An international research consortium with the participation of the German Center for Neurodegenerative Diseases (DZNE) and the Bonn University Hospital has identified 11 previously unknown genetic risk factors for Alzheimer's disease.
The genome of over 25,000 patients as well as more than 48,000 healthy controls was analyzed to this end. The results have been published in the scientific journal “Nature Genetics”.
Alzheimer’s disease is a common cause of dementia. It is triggered by the death of brain cells and occurs in two variants: The so-called familial variant is relatively rare. It is caused by certain mutations in the genome and usually manifests itself already before the age of 65. However, more than 90 percent of the cases occur at an older age. The exact causes of this “sporadic” form of the disease are enigmatic. However, it is known that a disease may be favored by genetic traits, even though it may not necessarily be triggered by it.
So far, 11 such risk factors were known. A further 11 have now been identified by a team of researchers from the US and Europe. For this several universities and research institutions collaborated within the framework of the “International Genomics of Alzheimer's Project” (IGAP).
Large amounts of data
“Such an endeavor is enormously complex and requires the cooperation of many partners. We in particular contributed clinical data. This included anonymous genetic data of about one thousand patients that are diagnosed with Alzheimer’s disease,” says Dr. Alfredo Ramirez, who is a researcher at the Department of Psychiatry and Psychotherapy of Bonn University Hospital.
The memory clinic played an important role, explains Professor Frank Jessen, who is Deputy Director of the Department of Psychiatry and Psychotherapy and also a researcher affiliated to the DZNE: “Longtime preparations are needed for such a study. On the basis of our memory clinic we have been in touch with people diagnosed with memory disorders for many years. Through this we have been able to build up an extensive repository of genetic data from patients. We made this data available for the study.”
“In the case of such genetic studies, it is ultimately a matter of comparing the genomes of patients and controls,” explains Dr. Tim Becker from the Bonn site of the DZNE. Within the framework of the now published study he focused in particular on the analysis of genetic data. “We searched for genetic traits that are prevalent in persons that have been diagnosed with the disease. In order to do so, genetic data from many people has to be compared. This is the only way to obtain meaningful results and to distinguish random signals from real findings.”
Important contributions also came from the Institute of Human Genetics of the Bonn University Hospital. “We genotyped samples of DNA. This is very similar to doing genetic fingerprinting,” says Professor Markus Nöthen, head of the Institute.
Screening the genome
The IGAP consortium studied the genome of a total of 74,046 people. Of these, more than 25,000 were diagnosed with Alzheimer’s disease, the others were controls. High performance computing assisted in the analysis of the huge amount of data.
Pivotal to the research were so-called genome-wide association studies (GWAS). The genome, with its billions of building blocks, was thereby not fully cataloged, but instead only examined at relevant positions. This type of screening saves time and money, while at the same time providing a good coverage. The researchers examined about seven million positions.
“We identified eleven positions in the human genome that were previously largely ignored. However, if certain alterations are present there, the probability of developing Alzheimer’s increases,” says Becker. “Yet, this increased risk does not necessarily lead to disease.”
So far the researchers do not yet know in detail what role the affected regions play. “Some of these genes are related to Amyloid-beta and tau proteins that are known to be relevant for the Alzheimer’s disease. With regard to the other critical regions, we can not say with certainty what role they play”, says Ramirez. “We assume that they have an effect, for example, on nervous connections and on transport processes occurring inside the nerve cells. In addition, the immune system seems to be involved. As a next step, it will be important to investigate this in more detail.”Original publication
Dr. Marcus Neitzert | idw
Human skin is an important source of ammonia emissions
27.05.2020 | Max-Planck-Institut für Chemie
Biotechnology: Triggered by light, a novel way to switch on an enzyme
27.05.2020 | Westfälische Wilhelms-Universität Münster
In living cells, enzymes drive biochemical metabolic processes enabling reactions to take place efficiently. It is this very ability which allows them to be used as catalysts in biotechnology, for example to create chemical products such as pharmaceutics. Researchers now identified an enzyme that, when illuminated with blue light, becomes catalytically active and initiates a reaction that was previously unknown in enzymatics. The study was published in "Nature Communications".
Enzymes: they are the central drivers for biochemical metabolic processes in every living cell, enabling reactions to take place efficiently. It is this very...
Early detection of tumors is extremely important in treating cancer. A new technique developed by researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The work is published May 25 in the journal Nature Nanotechnology.
researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from...
Microelectronics as a key technology enables numerous innovations in the field of intelligent medical technology. The Fraunhofer Institute for Biomedical Engineering IBMT coordinates the BMBF cooperative project "I-call" realizing the first electronic system for ultrasound-based, safe and interference-resistant data transmission between implants in the human body.
When microelectronic systems are used for medical applications, they have to meet high requirements in terms of biocompatibility, reliability, energy...
Thomas Heine, Professor of Theoretical Chemistry at TU Dresden, together with his team, first predicted a topological 2D polymer in 2019. Only one year later, an international team led by Italian researchers was able to synthesize these materials and experimentally prove their topological properties. For the renowned journal Nature Materials, this was the occasion to invite Thomas Heine to a News and Views article, which was published this week. Under the title "Making 2D Topological Polymers a reality" Prof. Heine describes how his theory became a reality.
Ultrathin materials are extremely interesting as building blocks for next generation nano electronic devices, as it is much easier to make circuits and other...
Scientists took a leukocyte as the blueprint and developed a microrobot that has the size, shape and moving capabilities of a white blood cell. Simulating a blood vessel in a laboratory setting, they succeeded in magnetically navigating the ball-shaped microroller through this dynamic and dense environment. The drug-delivery vehicle withstood the simulated blood flow, pushing the developments in targeted drug delivery a step further: inside the body, there is no better access route to all tissues and organs than the circulatory system. A robot that could actually travel through this finely woven web would revolutionize the minimally-invasive treatment of illnesses.
A team of scientists from the Max Planck Institute for Intelligent Systems (MPI-IS) in Stuttgart invented a tiny microrobot that resembles a white blood cell...
19.05.2020 | Event News
07.04.2020 | Event News
06.04.2020 | Event News
27.05.2020 | Information Technology
27.05.2020 | Physics and Astronomy
27.05.2020 | Earth Sciences